News + Font Resize -

Ranbaxy's Caverta overtakes Penegra of Zydus in July monthly sales, Silagra, Edegra degrow
Our Bureau, Mumbai | Tuesday, September 17, 2002, 08:00 Hrs  [IST]

Caverta, Ranbaxy's sildenafil citrate brand, has overtaken Penegra of Zydus Cadila in sales as per latest market figures available. Penegra used to have the largest sales amongst 20 odd sildenafil citrate brands circulating in the Indian market for last one year.

Market sources say that while Penegra recorded a turnover of Rs 81.32 lakh and a market share of 25 per cent in the month of July, Caverta had sales of Rs 86.44 lakh and a market share of 27 per cent. The growth of Penegra is 29 per cent while that of Caverta is 20 per cent higher at 49 per cent.

The first two brands together hold about half of the sildenafil citrate generic sales in the country. While Penegra comes from Zydus Cadila Healthcare Ltd, Ranbaxy Laboratories Ltd is the manufacturer of Caverta.

However, Penegra is still the number one in terms of annual sales. It has a turnover of Rs 8.44 crore while Caverta generated a business of Rs 8.33 crore in the period between August last year and July this year. Penegra has registered a growth of 89 per cent while Caverta has grown heavily by 169 per cent in the same period, once again indicating that Caverta is heading for the top slot.

The market share of Penegra in terms of annual sales is 25 per cent while that of Caverta is 24 per cent.

The number three products in the market are Silagra from city-based generics leader Cipla Ltd. It has a sale of Rs 4.04 crore in the year under consideration, a growth of 152 per cent and a market share of 12 per cent. In July sales, the Cipla product suffered a degrowth of 25 per cent to record a market share of just six per cent and a sales of Rs 20.1 lakh.

Cipla has another product in the market under the name Progra that has also recorded a negative growth of 94 per cent in July and has a sales of Rs 16,000.

The ED segment itself is growing at 141 per cent on an annual basis with a total turnover of Rs 34 crore. On a monthly basis, the growth is 38 per cent for a segment turnover of 3.19 crore.

Sun Pharmaceutical Industries Ltd's Edegra, which had an annual sales of Rs 2.97 crore, a market share of 9 per cent and a growth of 60 per cent, found itself degrowing at 13 per cent in July. The month's turnover stands at Rs 22.78 lakh and a market share of 7 per cent.

Post Your Comment

 

Enquiry Form